A major South American tribunal has backed the Colombian government in a high-profile dispute over a crucial HIV medicine. Two years ago, Colombia issued a compulsory license for an HIV drug marketed by ViiV Healthcare. A compulsory license is a legal tool that allows a government to permit the production or sale of a patented product without the consent of the patent owner, typically to address urgent public health needs.
The Court of Justice of the Andean Community, a tribunal that settles trade and intellectual property disputes for Bolivia, Colombia, Ecuador, and Peru, upheld the move. The court ruled that Colombia properly justified its decision to issue the license on the grounds of public interest. Additionally, the tribunal confirmed that the government met its legal obligations by setting a specific expiration date for the licensing period.
Every cell in our body relies on a strict internal recycling system to clear out old or unnecessary proteins. The FBXW7 gene plays a critical role in this process. When people are born with mutations in this gene, known as germline variants, they can develop a distinct neurological condition. Affected children typically face early developmental delays, low muscle tone known as hypotonia, and difficulties learning language.
Researchers have found that most of these mutations cluster in a specific area of the gene called the WD40 domain, which acts as a sensor to recognize which proteins need to be degraded. When this sensor is broken, proteins that regulate cell division and growth are not cleared away properly. The buildup of these critical proteins ultimately disrupts normal development.
Interestingly, this same genetic error also carries a risk for a type of childhood kidney cancer known as Wilms tumor. The cancer develops through a classic "two-hit" model. A child is born with one mutated copy of the FBXW7 gene, which acts as the first hit. If a second, spontaneous mutation occurs directly in the kidney tissue later on, a tumor can form.
Glioblastoma is a highly aggressive form of brain cancer. Curiously, these tumors are often surrounded by specific immune cells called microglia and macrophages. These cells feature a unique protein on their surface known as the P2X7 receptor. Until now, scientists have lacked a specialized medical imaging tool to clearly see these tumor-associated immune cells in living bodies. To solve this problem, researchers have developed a new radioactive tracing compound named FJR01.
FJR01 was built to be used with SPECT, a standard medical imaging technique that creates three-dimensional pictures of the inside of the body. The tracer acts like a molecular homing beacon. In laboratory tests, it showed a high affinity for binding to human P2X7 receptors. When the research team injected the radioactive tracer into a rat model of brain cancer, the SPECT scans successfully showed the compound gathering precisely at the focal point of the tumor.
Early safety checks look promising. Tissue studies and mathematical models estimating how the tracer might act in humans suggest it has a favorable safety profile with good potential for future clinical use. However, this research is still in its very early preclinical stages. Right now, the tracer's effectiveness and movement through the body have only been tested in healthy mice and rat brain cancer models, meaning it will be a while before this tool is evaluated in human patients.
As we get older, our bodies undergo changes that can make illnesses like breast cancer more dangerous. Scientists have recently discovered a major reason why this happens. They found that aging drastically increases the spread of breast cancer to the lungs, a process known as metastasis. This age-related spread is driven by a specific protein on the surface of our cells called RAGE. RAGE acts as an amplifier for inflammation. As we age, it becomes increasingly active and fuels a harmful environment that helps tumors invade other parts of the body.
To understand this process, researchers looked at mouse models of triple-negative breast cancer, a particularly aggressive form of the disease. They observed that older mice developed significantly more lung metastases than younger ones. However, when the scientists genetically removed the RAGE receptor or blocked it using an experimental drug called azeliragon, the age-dependent spread of the cancer essentially stopped. This showed that the cancer cells were directly relying on this inflammatory pathway to move and grow.
The team then looked to see if this phenomenon holds true in humans. By analyzing data from more than 1,000 breast cancer patients, they confirmed that high levels of the gene that creates RAGE, along with other aging-related biological markers, were linked to worse survival outcomes. This connection was especially strong in older women, suggesting that the RAGE pathway is a crucial driver of cancer progression in older adults.
For many patients with estrogen receptor-positive breast cancer, the disease eventually spreads to the bones. To prevent the cancer from breaking down bone tissue, doctors often prescribe a drug called denosumab. This treatment works by blocking a specific protein pathway required to activate bone-destroying cells known as osteoclasts. However, the cancer often finds a way around this roadblock. Nearly 40 percent of patients on denosumab eventually experience further bone damage as their tumors become resistant to the therapy.
Researchers have now discovered exactly how these tumors bypass the medication. They found that the cancer cells activate an entirely independent pathway to keep destroying bone. The tumors produce a specific genetic molecule and package it into large cellular delivery vehicles called oncosomes. These vehicles are sent directly into immature bone-destroying cells. Once inside, the genetic payload recruits a protein called CARM1 to activate specific genes, locking the osteoclasts in an active state. This creates a self-reinforcing cycle of bone loss that standard drugs simply cannot stop.
Armed with this new understanding, the research team tested a way to short-circuit this alternative pathway. By using an experimental compound called TP-064 to inhibit the CARM1 protein, they successfully suppressed the formation of new bone-destroying cells. This effectively halted bone metastasis in laboratory models that were previously resistant to standard denosumab treatment.
Amyotrophic lateral sclerosis, commonly known as ALS, is a devastating disease that gradually destroys the nerve cells responsible for movement. For years, scientists have puzzled over why the condition progresses rapidly in some patients while others survive much longer. Now, researchers at Northwestern University have uncovered a domino-like cascade that helps explain how the disease unfolds. Rather than a single catastrophic event, ALS appears to start with an internal breakdown inside motor neurons involving a toxic buildup of a protein called TDP-43. This initial damage then triggers a secondary, highly destructive response from the body's own immune system.
By examining blood and spinal cord samples from hundreds of living and deceased patients, the scientists mapped out exactly where and how this immune reaction occurs. They discovered that inflamed immune cells from the bloodstream travel into the central nervous system, gathering directly at the sites where motor neurons are dying and toxic proteins are accumulating. Patients with the fastest disease progression had the most intense spinal cord inflammation and higher activity in complement genes, which produce proteins that act as the body's first line of immune defense against damage.
Interestingly, the study also revealed that this immune response looks different depending on the root cause of the patient's condition. By analyzing the genetic instructions inside individual cells, the researchers found distinct immune patterns when comparing genetic and non-genetic forms of ALS. This suggests that the immune system reacts uniquely to different variations of the disease.
Optic pathway gliomas are tumors that grow along the nerves connecting the eyes to the brain. When these tumors appear in children, doctors face a tough choice about how to treat them safely without damaging the child's vision. Surgery to remove part of the mass, a process known as tumor debulking, is common but comes with an unpredictable risk of making the child's eyesight worse.
To understand how to best protect a child's sight, researchers looked back at 192 pediatric patients who had partial tumor removal surgery at a single hospital over a 12-year period. They found that a child's eyesight right before surgery, called baseline visual acuity, is the strongest predictor of how well they will see long after the operation. Interestingly, children who started out with moderate vision were the most sensitive to the surgical process. For these kids, removing more of the tumor actually tended to result in worse vision over time.
The research team identified a clear pattern showing that less aggressive treatment is often safer. Taking out 50 percent or more of the tumor, waiting too long to operate, or using radiation therapy after surgery were all linked to poorer visual outcomes. Children under three years old also faced higher risks. Even the specific path the surgeon takes to reach the tumor makes a big difference. Approaching the tumor through the front and side of the skull helped protect vision, while coming straight down the middle of the brain increased the risk of vision loss.
One of the biggest hurdles in treating cancer is that tumors often outsmart the drugs designed to destroy them. For a long time, scientists have tried to understand this resistance by zooming in on single biological glitches, like isolated genetic mutations or specific signaling pathways. However, this narrow focus misses the big picture of how tumors actually survive and adapt inside the human body.
To solve this puzzle, researchers are proposing a fresh way to look at the disease. Instead of viewing a tumor as a simple clump of rogue cells, they suggest treating it as a complex, living ecosystem. This new theoretical framework looks at a triad of factors: the flexible nature of the cancer cells themselves, the immediate cellular neighborhood they live in (known as the microenvironment), and the overall physical state of the patient.
By combining these three levels, scientists can better track how tumors adapt to treatments over time. Just like an invasive species thriving in a changing forest, cancer cells use their surroundings and the body's own systems to build their defenses. Understanding this dynamic evolution is the first step toward breaking it.
Prostate cancer remains a major global health challenge. While many patients initially respond well to standard hormone treatments, the disease often becomes resistant over time. This leads to an advanced form of the illness with very few treatment options. Scientists have recently discovered that a specific protein called ALDH7A1 helps drive this aggressive cancer growth, but finding drugs that can effectively block this protein has proven difficult.
To tackle this problem, researchers tested a library of unique chemical compounds and identified a new class of drugs that can successfully shut down the ALDH7A1 protein. These new compounds act as irreversible covalent inhibitors. In simple terms, they are designed to permanently lock onto a specific part of the target protein, completely disabling it.
When the researchers tested two of their most promising compounds on prostate cancer cells in the lab, the results were striking. The drugs reduced the ability of the cancer cells to survive, stopped them from migrating, and disrupted their normal growth cycle. The treatment works by blocking the target protein, which causes toxic molecules to build up inside the cancer cells and destroys them through severe oxidative stress. Crucially, the researchers found that these compounds are highly selective. They effectively ignored healthy cells and cells that do not heavily rely on the target protein, focusing their destructive power specifically on the vulnerable cancer cells.
Soft tissue sarcomas are cancers that develop in the muscles, fat, or other supporting tissues of the body. Historically, treating them with radiation meant many weeks of daily hospital visits. Now, researchers are confirming that a newer approach called hypofractionated radiotherapy is highly effective. This method delivers larger doses of radiation over a shorter total time period. Recent evidence shows that using this shorter course of radiation before surgery for tumors on the limbs or torso is just as effective as longer, traditional treatments, while offering a much more convenient schedule for patients.
Beyond changing the treatment schedule, doctors are also teaming up radiation with other powerful therapies. For patients with high-risk tumors, radiation is being combined with immunotherapies and targeted drugs like PARP inhibitors, which block certain enzymes that cancer cells need to repair themselves. At the same time, advanced imaging techniques like multiparametric MRI and specific tissue markers are helping doctors see exactly how a tumor is responding early in the process. This real-time feedback allows medical teams to adapt and personalize the radiation plan for each individual patient.
Researchers have discovered that altering how cancer cells generate energy might help the immune system recognize and fight colon cancer. The study focuses on a protein called MCJ, which normally acts like a brake on a cell's energy factories, known as mitochondria. When scientists removed this protein from lab-grown cancer cells, the cells ramped up their oxygen use and overall energy production, shifting away from their typical low-oxygen, sugar-burning state.
To see how this metabolic shift affected tumor growth, the researchers tested the altered cancer cells in mice. In mice lacking a functioning immune system, the tumors grew normally. However, in mice with healthy immune systems, the growth of these MCJ-deficient tumors was severely restricted. This indicates that forcing the cancer cells to burn oxygen rather than sugar somehow alerts the body's T-cells, which are specialized immune defenders, to step in and attack the tumor.
The team found similar patterns when analyzing genetic data from human colorectal cancer patients. Tumors with naturally low levels of the MCJ protein had higher rates of genetic mutations, greater genetic instability, and a stronger presence of infiltrating immune cells. While these findings are exciting, the research is still in an early preclinical phase. Because the study relies on cell lines, animal models, and historical data, scientists do not yet know if targeting this protein will be a safe or effective treatment for human patients.
Hormone receptor-positive (HR+) breast cancer is the most common form of the disease, making up 70 to 80 percent of all diagnoses. Doctors typically treat it using endocrine therapies, which block the hormones that fuel tumor growth. While these treatments have seen major advances, a persistent problem remains. Many tumors eventually develop a resistance to the therapy, leading to relapses and treatment failure.
To understand how tumors learn to evade these treatments, researchers are looking at a specific type of genetic material known as long non-coding RNAs, or lncRNAs. These molecules act like master switches inside the cell. In HR+ breast cancer, lncRNAs can change how estrogen receptors function, turn on alternative survival pathways, and alter both the genetic packaging and the physical environment around the tumor.
By manipulating these microscopic processes, lncRNAs directly control whether a tumor remains sensitive to hormone treatments or becomes resistant. Mapping out these specific cellular escape routes helps scientists understand exactly how cancer survives, revealing entirely new targets for future medicines.
